Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus INDICLOR.
FLURBIPROFEN SODIUM vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category D/X
Category C
NSAID
NSAID